S. Fava

472 total citations
22 papers, 288 citations indexed

About

S. Fava is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, S. Fava has authored 22 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in S. Fava's work include Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (4 papers) and Acute Myeloid Leukemia Research (3 papers). S. Fava is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (4 papers) and Acute Myeloid Leukemia Research (3 papers). S. Fava collaborates with scholars based in Italy, United States and Malaysia. S. Fava's co-authors include M Luoni, Anna Tosi, Angelo Tocci, Enrico Aitini, Luigi Mariani, M. Visini, G. Pinotti, G. Schieppati, Elena Beretta and Roberto Buzzoni and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

S. Fava

20 papers receiving 282 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Fava Italy 9 129 104 86 55 30 22 288
Minami Hashimoto Japan 9 132 1.0× 111 1.1× 152 1.8× 43 0.8× 10 0.3× 59 267
Bernard Nalet France 11 204 1.6× 172 1.7× 224 2.6× 200 3.6× 43 1.4× 22 511
Abdul Hamid El Chafic United States 9 198 1.5× 212 2.0× 305 3.5× 59 1.1× 24 0.8× 25 406
Yong Fang China 12 208 1.6× 124 1.2× 143 1.7× 101 1.8× 28 0.9× 41 400
Hatice Odabaş Türkiye 10 162 1.3× 194 1.9× 85 1.0× 24 0.4× 13 0.4× 59 325
P. Sandbichler Austria 11 190 1.5× 94 0.9× 291 3.4× 49 0.9× 43 1.4× 26 456
Daisuke Korenaga Japan 12 245 1.9× 137 1.3× 194 2.3× 98 1.8× 36 1.2× 30 445
Ahmet Dinççağ Türkiye 10 140 1.1× 75 0.7× 311 3.6× 63 1.1× 12 0.4× 25 377
Isabelle Iwanicki–Caron France 9 194 1.5× 77 0.7× 330 3.8× 183 3.3× 19 0.6× 16 449
Gandhi Lanke United States 9 87 0.7× 149 1.4× 129 1.5× 29 0.5× 10 0.3× 20 268

Countries citing papers authored by S. Fava

Since Specialization
Citations

This map shows the geographic impact of S. Fava's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Fava with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Fava more than expected).

Fields of papers citing papers by S. Fava

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Fava. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Fava. The network helps show where S. Fava may publish in the future.

Co-authorship network of co-authors of S. Fava

This figure shows the co-authorship network connecting the top 25 collaborators of S. Fava. A scholar is included among the top collaborators of S. Fava based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Fava. S. Fava is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Varrella, Stefano, Silvia Livi, Cinzia Corinaldesi, et al.. (2025). A comprehensive assessment of non-indigenous species requires the combination of multi-marker eDNA metabarcoding with classical taxonomic identification. Environment International. 199. 109489–109489. 1 indexed citations
2.
Luciani, Andrea, Luca Toschi, S. Fava, et al.. (2018). Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience. Annals of Oncology. 29. viii533–viii533. 6 indexed citations
3.
Roila, Fausto, Benedetta Ruggeri, Enzo Ballatori, et al.. (2015). Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Annals of Oncology. 26(6). 1248–1253. 24 indexed citations
4.
5.
Fagnani, Daniele, Marco Danova, Gabriella Farina, et al.. (2014). Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.. PubMed. 100(5). 491–8. 14 indexed citations
6.
Corso, Alessandro, Silvia Mangiacavalli, Luciana Barbarano, et al.. (2007). Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. Leukemia Research. 32(7). 1085–1090. 1 indexed citations
7.
Barni, Sandro, M. Visini, E. Piazza, et al.. (2007). 5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study.. PubMed. 27(4C). 3019–24. 1 indexed citations
8.
Luoni, M, et al.. (2004). Retroperitoneal hemorrhage following bone marrow biopsy.. PubMed. 79(1). 70–2. 11 indexed citations
9.
Bajetta, Emilio, Roberto Buzzoni, Luigi Mariani, et al.. (2002). Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Annals of Oncology. 13(2). 299–307. 105 indexed citations
10.
Riccardi, Alberto, Marco Danova, Silvia Brugnatelli, et al.. (2001). A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01). British Journal of Cancer. 85(2). 141–146. 8 indexed citations
11.
Brugnatelli, Silvia, Alberto Riccardi, Marco Danova, et al.. (2001). Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study. Oncology Reports. 8(4). 801–5. 8 indexed citations
12.
Riccardi, Alberto, Carmine Tinelli, Silvia Brugnatelli, et al.. (2000). Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer.. International Journal of Oncology. 16(4). 769–76. 22 indexed citations
13.
Brugnatelli, Silvia, M. Giordano, Marco Danova, et al.. (1998). Paclitaxel in anthracycline-treated breast cancer patients.. Oncology Reports. 5(4). 915–8. 3 indexed citations
14.
Fava, S., M Luoni, & Sabine Stioui. (1997). Pericarditis during interferon-alpha therapy in chronic myelogenous leukemia.. PubMed. 81(5). 484–484. 6 indexed citations
15.
Faggioli, Paola, Massimo De Paschale, Angelo Tocci, et al.. (1997). Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma.. PubMed. 82(1). 38–42. 45 indexed citations
16.
Riccardi, Alberto, Monica Giordano, Silvia Brugnatelli, et al.. (1995). ADVANCED BREAST-CANCER - A RANDOMIZED STUDY OF DIFFERENT DOSES OF EPIRUBICIN ASSOCIATED WITH FIXED DOSES OF CYCLOPHOSPHAMIDE AND 5-FLUOROURACIL. Oncology Reports. 2(4). 577–82. 1 indexed citations
17.
Tosi, Anna, Antonino De Paoli, S. Fava, et al.. (1995). Undifferentiated granulocytic sarcoma: a case with epidural onset preceding acute promyelocytic leukemia.. PubMed. 80(1). 44–6. 11 indexed citations
18.
Fava, S., et al.. (1994). [Prolymphocytic leukemia: the therapeutic strategy].. PubMed. 85(10). 496–501. 1 indexed citations
19.
Paoli, Antonino De, et al.. (1993). Idiopathic hypereosinophilic syndrome and "eosinophilic leukemia".. PubMed. 77(5). 430–2. 10 indexed citations
20.
Paoli, Antonino De, et al.. (1988). Granulocytic sarcoma: a case probably cured.. PubMed. 73(4). 313–6. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Minami Hashimoto Breakdown of academic impact, for papers by Bernard Nalet Breakdown of academic impact, for papers by Abdul Hamid El Chafic Breakdown of academic impact, for papers by Yong Fang Breakdown of academic impact, for papers by Hatice Odabaş Breakdown of academic impact, for papers by P. Sandbichler Breakdown of academic impact, for papers by Daisuke Korenaga Breakdown of academic impact, for papers by Ahmet Dinççağ Breakdown of academic impact, for papers by Isabelle Iwanicki–Caron Breakdown of academic impact, for papers by Gandhi Lanke
Rankless by CCL
2026